TABLE 3.
l-ascorbic acid per allele variation, μmol/L |
|||||||
Study | n | Minor homozygote (AA) | Heterozygote (AG) | Major homozygote (GG) | Per allele effect on standardized l-ascorbic acid | P | Variance explained by SNP, % |
BWHHS | 3438 | 52.61 (17.94, 87.28)2 | 38.61 (35.07, 42.14) | 43.69 (42.72, 44.66) | 0.17 (0.04, 0.30) | 0.01 | 0.19 |
MIDSPAN | 1291 | 39.30 (24.08, 54.52) | 45.02 (40.63, 49.42) | 49.68 (48.22, 51.14) | 0.16 (−0.01, 0.34) | 0.07 | 0.40 |
Ten Towns | 1477 | 64.0 (−520.49, 648.49) | 44.86 (40.99, 48.73) | 50.64 (49.36, 51.92) | 0.20 (0.01, 0.40) | 0.04 | 0.28 |
BRHS | 3740 | 21.53 (6.43, 36.62) | 27.55 (24.25, 30.85) | 30.31 (29.41, 31.21) | 0.18 (0.05, 0.30) | 0.01 | 0.21 |
Meta-analysis | 9946 | 33.35 (19.70, 46.99) | 38.94 (30.55, 47.34) | 43.57 (33.77, 53.37) | 0.18 (0.10, 0.25) | 3.34 × 10−6 | 0.28 |
EPIC | 6013 | 36.50 (27.24, 45.76) | 46.63 (45.06, 48.20) | 54.74 (54.21, 55.28) | 0.40 (0.31, 0.50) | 2.73 × 10−17 | 1.18 |
BRHS, British Regional Heart Study; BWHHS, British Women's Heart and Health Study; EPIC, European Prospective Investigation into Cancer; SNP, single nucleotide polymorphism.
Mean; 95% CI in parentheses (all such values).